Most people with hereditary angioedema (HAE) who received treatment with a 50 mg dose of the gene-editing therapy…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
The case of an elderly man who developed acquired angioedema associated with an underlying blood disorder called monoclonal gammopathy…
An algorithm that takes into account factors such as the frequency and location of swelling attacks may help distinguish chronic…
Regulatory authorities in Japan, the U.S., and the European Union have aligned on plans for a Phase 3 clinical trial…
Authorities in the European Union (EU) have agreed to review Kalvista Pharmaceuticals’ application requesting the approval of oral…
Astria Therapeutics is teaming up with Ypsomed, a Swiss-based company, to develop an autoinjector for its experimental treatment…
A single dose of the gene-editing therapy NTLA-2002 led to significant reductions in the number of swelling attacks among…
The oral medication Orladeyo (berotralstat) is now approved in Peru as a prophylactic, or preventive, treatment to reduce the…
KalVista Pharmaceuticals has started a clinical trial to test the oral medication sebetralstat as an on-demand treatment for…
Most hereditary angioedema (HAE) patients are able to take on-demand oral tablets of sebetralstat within 10 minutes of…